Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Neoplasms, Plasma Cell 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Anemia 1

Interventions

Cytarabine 166Cyclophosphamide 110Daunorubicin 88Methotrexate 83Etoposide 66Vincristine 63Mercaptopurine 55Rituximab 54Dexamethasone 54venetoclax 50fludarabine 47Doxorubicin 46Azacitidine 46Idarubicin 45Asparaginase 42Imatinib Mesylate 41Prednisone 39pegaspargase 37Thioguanine 36Radiotherapy 35Mitoxantrone 35Busulfan 31Peripheral Blood Stem Cell Transplantation 25Leucovorin 25Bendamustine Hydrochloride 25fludarabine phosphate 24Filgrastim 24obinutuzumab 23nilotinib 23Granulocyte Colony-Stimulating Factor 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Iron-Dextran Complex × Other hematologic neoplasm × Clear all
NCT00482716 2014-01-10

Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer

National Cancer Institute (NCI)

Phase 3 Unknown
80 enrolled
Classical hematologyLymphoidOther hematologic neoplasmPlasma cell

Anemia, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡